Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Alnylam
Alnylam
Alnylam makes case for lumasiran in infants ahead of FDA ruling
Fierce Biotech
Fri, 10/23/20 - 10:57 am
Alnylam
kidney disease
lumasiran
pediatric
FDA
Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?
Motley Fool
Sun, 10/18/20 - 08:32 pm
Alnylam
Vir Biotechnology
RNAi
vaccines
COVID-19
Alnylam Posts Positive Results of Groundbreaking Phase III PH1 Trial
BioSpace
Thu, 10/1/20 - 11:28 am
Alnylam
lumasiran
clinical trials
Primary Hyperoxaluria
Alnylam phase 3 links lumasiran to 'clinically significant' improvement in infants
Fierce Biotech
Wed, 09/30/20 - 10:35 am
Alnylam
clinical trials
lumasiran
RNAi
PH1
Blackstone finalizes R&D pact with Alnylam as part of earlier $2 billion investment
Endpoints
Mon, 08/17/20 - 10:36 am
Blackstone
Alnylam
R&D
Alnylam's RNAi therapy Givlaari shows lasting effect one year into treatment, new data show
Fierce Pharma
Tue, 06/30/20 - 10:51 am
Alnylam
RNAi
Givlaari
acute hepatic porphyria
Alnylam sets up 3rd potential RNAi approval with a showcase of positive lumasiran data
Endpoints
Sun, 06/7/20 - 10:32 pm
Alnylam
clinical trials
RNAi
lumasiran
PH1
Alnylam nabs speedy review, setting up 3rd possible approval in 3 years
Endpoints
Tue, 05/26/20 - 11:12 am
Alnylam
RNAi
FDA
drug approvals
lumasiran
hyperoxaluria
Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral
Fierce Biotech
Mon, 05/4/20 - 10:37 am
Alnylam
Vir Biotechnology
COVID-19
RNAi
clinical trials
Alnylam's vutrisiran gets fast-track treatment at the FDA
Fierce Biotech
Tue, 04/14/20 - 09:44 am
Alnylam
RNAi
FDA
hATTR
vutrisiran
fast track
Blackstone backs Alnylam with up to $2B investment
BioPharma Dive
Mon, 04/13/20 - 09:50 pm
generics
Alnylam
Blackstone
RNAi
Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1
Pharmaceutical Business Review
Wed, 04/8/20 - 10:51 am
Alnylam
Primary Hyperoxaluria
FDA
lumasiran
After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration
Endpoints
Mon, 04/6/20 - 10:29 am
Alnylam
Dicerna
John Maraganore
Douglas Fambrough
RNAi
Merck
Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19
Pharmaceutical Business Review
Fri, 04/3/20 - 11:15 am
Vir Biotechnology
Alnylam
COVID-19
RNAi
drug development
Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)
Pharmaceutical Business Review
Thu, 03/26/20 - 10:22 am
Alnylam
RNAi
Gen
Onpattro
Turkey
hATTR amyloidosis
Alnylam, Vir team up to develop siRNAs to tackle COVID-19
Fierce Biotech
Wed, 03/4/20 - 10:52 am
Alnylam
Vir Biotechnology
RNAi
coronaviruses
COVID-19
siRNA
Ex-Sanofi chief Olivier Brandicourt, current Blackstone advisor, jumps on Alnylam board
Endpoints
Fri, 02/28/20 - 10:44 am
Sanofi
Olivier Brandicourt
Alnylam
With Rising Drug Prices a Concern, Some Companies Enact Their Own Control Plans
BioSpace
Wed, 01/15/20 - 10:59 am
drug pricing
Roche
Eli Lilly
Amgen
Alnylam
Sanofi
JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval
Fierce Pharma
Tue, 01/14/20 - 10:44 am
Alnylam
RNAi
Givlaari
John Maraganore
JPMHC 2020
3 Rare Disease Drug Launches to Watch in 2020
Motley Fool
Sat, 01/4/20 - 07:38 pm
Global Blood Therapeutics
sickle cell disease
Oxbryta
Novartis
SCD
Adakveo
Alnylam
Givlaari
acute hepatic porphyria
FDA
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »